
NYSE:SYK
This summary was created by AI, based on 7 opinions in the last 12 months.
Stryker Corp (SYK) is facing a challenging environment in the medtech sector, characterized by weakness due to a post-Covid normalization and ongoing issues, including a cybersecurity attack that affected production. Despite these hurdles, experts largely recognize Stryker's strong market position, particularly in orthopedics, which continues to be a profitable segment for U.S. hospitals. The company has a robust relationship with medical professionals and is expected to grow its revenue at high single-digit rates. Analysts predict significant earnings growth, with a projected EPS of $15 by 2027, supported by an attractive valuation. As the population ages, the demand for artificial joints and robotic-assisted surgeries is expected to rise, positioning Stryker favorably in the long term.
Problem with the chart right now is it's making a lower high and a lower low. Looks like we just took out the last low. In the near term, that's a downtrend. He doesn't buy into downtrends or ride downhill rollercoasters. If it does decide to stop, reasonable chance that it will stop near old breakout point, ~$300. If it finds support and bounces off, could be a great time to buy.
Wonderful business, one of the best operators in healthcare. Balance sheet back to being clean and ready to make acquisitions. Expects extremely strong results. A leader, and gaining market share. Valuation is pricey, needs to deliver future gains, so stock's hit a wall. He's still buying, loves it long term.
(Analysts’ price target is $372.00)Sales machine. Market leader in joint replacement and medical products. Post-pandemic backlogs still huge. Double-digit topline revenue growth last few years, should continue. Acquisitive. Good free cashflow. Still growth in EMs. Valuation's run up, but he's not selling.
Great story. Medical devices is a really important area of healthcare. Tremendous brand loyalty from end-user, plus a demographic play. Great operating margins and quarterly numbers, which will just keep on getting better. Lots of growth internationally. Yield is 0.9%.
(Analysts’ price target is $350.67)Medical devices. Joint replacements. Huge backlog due to Covid. Costs increased from supply chains and labour, but now sorted out. Really improves quality of life. Great business, lots of growth from aging demographics. Lots of growth internationally, too. Once a doctor "buys in", tremendous brand loyalty. Yield is 1%.
(Analysts’ price target is $318.71)It is in the medical devices field producing parts for artificial knees, hips, etc. and improving patient quality of life. Surgeons tend to stick with the same products so there is a stability to its income. The backlog from Covid is being decreased but there is room to grow internationally and an aging population needs more of these surgeries. 72% of its business comes from the U.S. and the rest from emerging markets and the developed world. They have lots of free cash flow to buy other companies. Buy 18 Hold 11 Sell 1
(Analysts’ price target is $314.49)Doing well given the backlog in surgeries. 73% of their business is in the US, but there's growth in emerging markets where they also operate. Doctors stick with their products and seldom change. Also, aging demographics help. They could make acquisitions, which will benefit them.
(Analysts’ price target is $311.03)
Good products, good reputation. Good long-term investment in the medical device area. If you own it, keep holding. Her exposure to the space is via ABT and JNJ.
(Analysts’ price target is $379.00)